Clinical trials: C-difficile
Clostridium Difficile-Associated Diarrhea, Clostridium Enterocolitis
A Study of GT160-246 Versus Vancomycin in Patients With Clostridium Difficile-Associated Diarrhea
Approximately 300 patients will be entered into this study taking place throughout the United States, Canada and the United Kingdom.
- Conditions
- Clostridium Difficile-Associated Diarrhea, Clostridium Enterocolitis, Clostridium Difficile Diarrhea, Antibiotic-associated Colitis
- Trial name
- NCT00034294
- Testing
- GT160-246
- Where
- 99 sites in United States, Canada and 2 more
- Volunteers
- 300 people
- Sponsor
- Genzyme, a Sanofi Company
C. Difficile
Pre-emptive Prevention for Patients at High Risk for Hospital-onset Clostridioides Difficile
Clostridioides difficile (C. difficile) is the most common healthcare-associated pathogen, causing >500,000 infections and >29,000 deaths per year in the US.
- Trial name
- NCT05389904
- Testing
- Arm 1: Routine care, Arm 2: Preemptive C. difficile infection prevention bundle
- Where
- United States
- Volunteers
- 261 people
- Sponsor
- Brigham and Women's Hospital
Urinary Tract Infections
Diagnosis, Antibiotic Prescribing Practices and Outcomes of cUTI in an Outpatient Setting
This prospective, multicenter, comparative cohort observational study is to determine if Guidance® UTI pathway compared to traditional diagnostic pathways reduces the rates of empiric antibiotic therapy, adverse events, and…
- Trial name
- NCT05091931
- Where
- 2 sites in United States
- Volunteers
- 3,308 people
- Sponsor
- Pathnostics
Recurrent C. Difficile Associated Diarrhea
Fresh, Frozen or Lyophilized Fecal Microbiota Transplantation for Multiple Recurrent C. Difficile Associated Diarrhea
The objective of the study is to investigate the efficacy of fresh, frozen or lyophilized fecal microbiota transplantation (FMT) via colonoscopy in patients with recurrent C. difficile associated diarrhea (RCDAD).
- Trial name
- NCT02318992
- Testing
- Fecal Microbiota
- Where
- United States
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center, Houston
Clostridium Difficile
To Evaluate the Impact of SBI on C. Difficile in Hospitalized UC Patients
The effects of serum-derived bovine immunoglobulin/protein isolate (SBI) will be evaluated and compared to matching placebo in two distinct patient populations: I.
- Trial name
- NCT02730325
- Testing
- Serum-derived bovine immunoglobulin/protein isolate (SBI)
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Northwestern University
Recurrent C. Difficile Infection
A Trial of CP101 for the Prevention of Recurrent CDI (PRISM4)
This is a Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of the Efficacy, Safety, and Tolerability of a Single Oral Administration of CP101 for the Prevention of Recurrent Clostridioides difficile Infection (PRISM4).
- Trial name
- PRISM4 (NCT05153499)
- Testing
- CP101
- Where
- 68 sites in United States, Canada
- Volunteers
- 19 people
- Sponsor
- Finch Research and Development LLC.
Clostridoides Difficile Associated Disease
To Understand the Safety and Effects of a C. Difficile Vaccine With New Adds-Ons That Will Be Given to Healthy Adults
An antibody is a substance your body makes to fight off infection. This study will explore the safety and antibody response of a vaccine to prevent severe diarrhea caused by a germ called Clostridoides difficile (C. diff).
- Trial name
- NCT05805826
- Testing
- C. difficile vaccine (previously studied formulation)., C. difficile vaccine formulation 1., C. difficile vaccine formulation 2.
- Where
- 23 sites in United States
- Volunteers
- 936 people, healthy volunteers welcome
- Sponsor
- Pfizer
Clostridioides Difficile Infection
Lifestyle and Recurrent Clostridioides Difficile Infection (CDI)
This study aims to evaluate the impact of diet on the gut microbiome in adults with Clostridioides difficile infection (CDI). Eligible participants will be randomized and receive meals plus different types of health counseling.
- Trial name
- NCT07613645
- Testing
- Health counseling sessions, Diet (control diet), Diet (experimental diet)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Michigan
Clostridium Difficile Associated Diarrhea
A Safety, Tolerability and Pharmacokinetic Study of Two Formulations of Metronidazole Versus Immediate Release Metronidazole in Patient With C. Difficile Colitis
Clostridium difficile bacteria can be a cause of significant diarrheal disease, particularly in people who have taken potent antibiotics. When C.
- Trial name
- NCT01559545
- Testing
- Metronidazole, Metronidazole-DRF1, Metronidazole-DRF2
- Where
- 12 sites in India
- Volunteers
- 60 people
- Sponsor
- Dr. Reddy's Laboratories Limited
Clostridium Difficile
C Difficile Near-patient Diagnostics
The investigators will conduct a two-period, two-intervention, cluster randomized crossover (CRXO) designed study at Foothills Hospital in Calgary, Alberta.
- Trial name
- NCT03857464
- Testing
- Near Patient Testing, SOP for C. difficile diagnostics
- Where
- 2 sites in Canada
- Volunteers
- 3,816 people
- Sponsor
- University of Calgary
Moderate Clostridium Difficile Infection
Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections
This study will assess the safety and efficacy of multiple daily dosing of oral LFF571 in patients who have moderate Clostridium difficile infections.
- Trial name
- NCT01232595
- Testing
- LFF571, Vancomycin (POC)
- Where
- 18 sites in United States, Canada
- Volunteers
- 109 people
- Sponsor
- Novartis Pharmaceuticals
Clostridioides Difficile Infection
Ursodeoxycholic Acid in C. Difficile Infection
The primary objective of the study is to assess tolerability and adherence to treatment with ursodeoxycholic acid
- Trial name
- NCT05526807
- Testing
- Ursodeoxycholic acid
- Where
- United Kingdom
- Volunteers
- 6 people
- Sponsor
- Nottingham University Hospitals NHS Trust
Clostridium Difficile Infection
MET-2 Clinical Study for Recurrent Clostridium Difficile Infection (CDI)
MET-2 clinical study is an Open label, single center, multiple dose pilot study of 19 patients. The study is designed to measure the resolution of diarrhea as well as the feasibility of administration and safety of MET-2 for the…
- Trial name
- NCT02865616
- Testing
- MET-2, Vancomycin
- Where
- Canada
- Volunteers
- 19 people
- Sponsor
- NuBiyota
Ventilator Associated Pneumonia (VAP), Other Infections
Probiotics: Prevention of Severe Pneumonia and Endotracheal Colonization Trial (PROSPECT): A Feasibility Clinical Trial
Probiotics are commercially available live bacteria thought to have health benefits when ingested. A literature review of probiotic studies in the intensive care unit (ICU) found that in patients who receive probiotics, there is…
- Conditions
- Ventilator Associated Pneumonia (VAP), Other Infections, Antibiotic-Associated Diarrhea, C-Difficile
- Trial name
- PROSPECT (NCT01782755)
- Testing
- L. rhamnosus GG - Probiotic
- Where
- 14 sites in United States, Canada
- Volunteers
- 150 people
- Sponsor
- McMaster University
Clostridium Difficile
Fecal Transplant for Pediatric Patients Who Have Recurrent C-diff Infection
C-diff infection often causes belly pain and diarrhea and can be very hard to treat with medicine. One of the possible reasons that C-diff infection is hard to treat is because there is too much "bad" bacteria in the colon.
- Trial name
- FMT (NCT02134392)
- Testing
- Fecal Microbiota Transplantation
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Jonathan Gisser
Clostridium Difficile Infection
Treatment of C. Difficile Infection With Fecal Microbiota Transplantation (FMT)
The purpose of this study is to treat children with severe, moderate, resistant or relapsing C. difficile infection and to determine the changes in the intestinal microbiome (all of the bacteria living in the intestines) in…
- Trial name
- NCT01842347
- Testing
- Fecal microbiota
- Where
- United States
- Sponsor
- Medical College of Wisconsin
Clostridium Difficile, Inflammatory Bowel Disease
Fecal Microbiome Transplant
Fecal Microbiota Transplant (FMT) in pediatric patients with recurrent C. Difficile with or without Inflammatory Bowel Disease (IBD) The aims of this study are to determine the safety and efficacy of FMT treatment in pediatric…
- Conditions
- Clostridium Difficile, Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
- Trial name
- NCT02636517
- Testing
- Fecal Microbiota Transplant
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Judith Kelsen
Clostridium Enterocolitis, Pseudomembranous Colitis
Vancomycin vs. Nitazoxanide to Treat Recurrent C. Difficile Colitis
The purpose of this study is to compare the outcome of treatment with nitazoxanide vs. vancomycin for diarrheal disease due to Clostridium difficile in patients who have failed previous treatment with metronidazole.
- Conditions
- Clostridium Enterocolitis, Pseudomembranous Colitis, Antibiotic-Associated Colitis
- Trial name
- NCT00304889
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Michael E. DeBakey VA Medical Center
Clostridium Difficile, Clostridium Difficile Infection
FQ Restriction for the Prevention of CDI
This study evaluates the effectiveness of a new intervention, fluoroquinolone (FQ) Preprescription Authorization (PPA) strategy, to reduce and prevent Clostridium difficile infection (CDI) in hospital intensive care units (ICUs).
- Conditions
- Clostridium Difficile, Clostridium Difficile Infection, C Difficile Colitis
- Trial name
- FIRST (NCT03848689)
- Testing
- fluoroquinolone preprescription authorization, Control
- Where
- 7 sites in United States
- Volunteers
- 5,871 people
- Sponsor
- University of Wisconsin, Madison
Clostridium Difficile Infection Recurrence
Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff
Subjects with recurrent C. difficile infection will receive an oral dose of CP101 capsules one time in Treatment Group I or matching placebo one time in Treatment Group II.
- Trial name
- PRISM3 (NCT03110133)
- Testing
- Full Spectrum Microbiota
- Where
- 58 sites in United States, Canada
- Volunteers
- 206 people
- Sponsor
- Finch Research and Development LLC.